Discover GAP-PS technology for manufacturing your peptides
GAP-PS is a next-generation TAPS method that provides a sustainable and cost-effective solution to what is already a major bottleneck in peptide supply.
Our GAP-PS technology (Group Assisted Purification Peptide Synthesis) tackles the traditional challenges of peptide manufacturing by combing TAPS with solvent anchoring technology, leading to enhanced molecular control and a method that is highly capable, scalable, and sustainable.
Innovation in peptide manufacturing: Get new data showing GAP-PS is more than just another TAPS technology.
Want to learn more? Download our latest data here.
STAY TUNED – MORE INFORMATION TO FOLLOW… Register your interest to stay updated on our latest activities…
WATCH DR. COLE SEIFERT’S LIVE PRESENTATION AT TIDES USA 2026
Discover more about our GAP-PS and its ability to unlock SPPS-like capability and operability in solution phase.
1. Understanding the GLP-1 Supply Challenge
a. Understand the challenges driving GLP-1 drug substance supply bottlenecks and the limitations of traditional technologies
2. Introducing Tag-Assisted Peptide Synthesis (TAPS)
a. Discuss potential and current limitations of TAPS technologies
b. Understand barriers to wider TAPS adoption as a solution to the supply chain challenges
3. GAP-PS and Solvent Anchoring Advantages
a. Discuss solvent anchoring technology, how it improves solubility control, and how it enhances capability and operational efficiency in GAP-PS
b. Detailed example data on TZP fragments demonstrate the effectiveness of this technology.
c. Improved sustainability profile vs current methods.
Discover GAP-PS technology for your peptide therapeutics
GAP-PS is an emerging synthesis method that could provide a sustainable and cost-effective solution to what is fast becoming one of the major therapeutic supply challenges of our era.
Our GAP-PS technology (Group Assisted Purification Peptide Synthesis) tackles the traditional challenges of peptide manufacturing (namely reducing consumption of expensive raw material and reducing hazardous waste) to make complex synthetic peptide manufacturing more easily scalable, economical, and sustainable for large-scale commercial production.
Get in touch to learn more about our proof-of-concept study for peptide therapeutics.
Want to learn more? Download our exclusive whitepaper here.